Novel Compounds for the Treatment and Prevention of Autism

Avraham Yosefa, HUJI, School of Medicine - IMRIC, School of Public Health
Berry Elliot, HUJI, School of Medicine - IMRIC, School of Public Health

Categories	Prevention &Treatment
Development Stage	In vivo proof of concept; ongoing research
Patent Status	Provisional patent application filed
Market	The prevalence of autism is increasing worldwide and is estimated at between 0.5–2.0% (for autism spectrum disorders (ASDs) it is 1 in 68 children in the United States).

Highlights

Novel compound administered to the mother during pregnancy or after birth to newborns of families predisposed to "autism" has the potential to prevent /ameliorate autistic symptoms.
No side Effects in animal models. These results support further clinical studies.

Our Innovation

A novel compound that can be administered to mothers during pregnancy or after birth of newborns in families predisposed to "autism"– it has the potential to prevent /ameliorate autistic symptoms.
a safe non-teratogenic natural occurring compound that can be consumed safely by human in vivo and in vitro models, both as a preventive and therapeutic drug in animal models of autism.
When administered to mice this compound reduces significantly restricted and stereotyped behaviors and interests. Moreover it significantly increased social interactions and communication in offspring.

Development Milestones

Seeking funding for ongoing research and clinical trial.

The Opportunity

An estimated 1 in 68 children in the United States develops autism (about 77 million children in USA)